Send
Send
Print
Print

Press Releases

Flux RSS
 
April 12, 2010
bioMérieux Introduces Myla™ at ECCMID: New Informatics Solution to Transform the Microbiology Laboratory
Innovative software:
  • consolidates and transforms microbiology laboratory data into actionable information for treatment decisions
  • recaptures time for lab managers through efficiency gains and full control of lab workflow
A world leader in in vitro diagnostics, bioMérieux presented Myla™, a paradigm-shifting software application, at the European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Austria. Myla is a browser-based application that provides microbiology laboratory managers and technicians with a set of tools to revolutionize the way they work. It was designed by microbiologists for microbiologists to recapture the time spent on information retrieving and reporting activities through improved connectivity, laboratory workflow and information management. For more information, visit www.mylahelps.com.
Read More
December 1, 2009
bioMérieux’s TEMPO® Gains Approval for Testing E. coli in Food Samples
bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce that TEMPO® EC, an automated quality indicator test for the fast enumeration of Escherichia coli in food products, has been granted Official Methods of Analysis (OMA) approval by AOAC INTERNATIONAL. This added level of certification assures TEMPO EC users that the test meets stringent AOAC standards for excellence in indicator testing.
Read More
November 17, 2009
bioMérieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment
bioMérieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, based on emerging biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings, subject to regulatory approvals. Over 500,000 new cases of breast cancer are diagnosed each year in the US and Europe alone and predictive tests have been shown to improve outcomes for these patients.
Read More
November 10, 2009
bioMérieux’s VIDAS® System Simplifies the Detection of Salmonella & E. coli O157 Including H7 Strains for the Meat Industry
bioMérieux, a world leader in the field of in vitro diagnostics, today announced that VIDAS® Salmonella Xpress (SLMX) and VIDAS® UP E. coli O157 (Including H7) kits have been validated by AFNOR Certification according to the ISO 16140 standard. These validations cover the testing of raw beef and veal.
Read More
November 6, 2009
bioMérieux Launches a Molecular Diagnostic MRSA Test on its EasyQ® Automated Platform
Methicillin Resistant Staphylococcus aureus (MRSA) is the most prevalent multi-drug resistant bacteria and a growing threat to health. bioMérieux, a world leader in the field of in vitro diagnostics, today launched NucliSENS EasyQ® MRSA, a new automated test for Methicillin Resistant Staphylococcus aureus (MRSA), one of the leading causes of healthcare-associated infections. NucliSENS EasyQ MRSA is CE marked and bioMérieux will be submitting for 510(k) approval with the U.S. Food and Drug Administration in the first half of 2010.
Read More
October 28, 2009
chromIDTM MRSA Launched in U.S. bioMérieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal
Chromogenic media provides cost-effective MRSA identification for hospitals and labs.
Read More
July 24, 2009
bioMérieux is Adapting Production to Support Global Vaccine Production Effort in the Fight Against Influenza A/H1N1
bioMérieux, a world leader in in vitro diagnostics, is increasing its production to support the global effort to fight the Influenza pandemic. The company’s culture media for sterility testing* is used by vaccine manufacturers during the quality control of their production process to help ensure product safety. Sterility testing is critical for the control and release of vaccines on the market.
Read More
June 30, 2009
bioMérieux Launches VIDAS® EBV, a New Test for the Diagnosis of Infectious Mononucleosis
bioMérieux, a world leader in the field of in vitro diagnostics, today launched VIDAS® EBV for the detection of the Epstein-Barr virus (EBV). This virus causes 80% of cases of infectious mononucleosis, which is often known as “the kissing disease” because it is transmitted through saliva.
Read More
March 16, 2009
bioMérieux - 2008 Financial Results
The Board of Directors of bioMérieux, a global leader in the field of in vitro diagnostics, met on Friday, March 13 to approve the consolidated financial statements for the year ended December 31, 2008. The meeting was chaired by Alain Mérieux and attended by the Statutory Auditors.

  • Strong sales growth: +9.8%, at constant exchange rates, including business development
  • Improved operating margin before non recurring-items at 16.8% of sales
  • Substantial R&D and manufacturing investments
  • Three strategic acquisitions and expansion of international network

Read More
January 20, 2009
bioMérieux - 2008 Business Review
bioMérieux, a global leader in the field of in vitro diagnostics, released its business review for fourth-quarter and full-year 2008.

2008 Sales
  • Up 7.5% at constant exchange rates and scope of consolidation (like-for-like)
  • Up 9.8% at constant exchange rates, including business development agreements

Read More